To experimentally validate the prediction that cotargeting KDM4C and GSH pathways could overcome cisplatin resistance, we tested the effects of combined cisplatin, BSO and QC6352 treatment in six basal breast cancer cell lines with varying KDM4C amplification and BRCA1 mutation status and GSH metabolic subtypes (Supplementary Fig. 3a). Here, KDM4C is linked to breast carcinoma.